Bipartisan prescription drug reform to cut drug prices
Advance prescription drug reforms to cut drug prices.
Occurrences
Bipartisan prescription drug reform to cut drug prices
Bipartisan prescription drug reform to cut drug prices
The Grassley Wyden Bill to reduce prescription drug prices by making sure that one year over another year you can't have more than an increase in drug prices of CPI.
Bipartisan prescription drug reform to cut drug prices
Bipartisan prescription drug reform to cut drug prices
Evidence
The campaign page said Grassley worked to lower drug prices through bipartisan legislation and listed as future work: “Bipartisan prescription drug reform to cut drug prices.”
Congress.gov lists Grassley as an original cosponsor of S.127. The bill would restrict PBM practices, require PBM reporting to the FTC, and authorize FTC and state attorney general enforcement. It was ordered reported favorably and placed on the Senate legislative calendar, but not enacted in the 118th Congress.
Grassley’s Senate office said he was an original cosponsor of the PBM Price Transparency and Accountability Act and that Grassley-led provisions would increase PBM reporting, require NADAC survey participation, and ban PBM spread pricing in Medicaid.
Congress.gov records H.R.7148 as Public Law 119-75. The enrolled text includes PBM accountability provisions, including requirements for Part D PBM agreements, limits on PBM remuneration to bona fide service fees, pass-through treatment for rebates and discounts, reporting, audit rights, and enforcement funding.
The official Senate roll call shows H.R.7148 passed the Senate 71-29 on January 30, 2026, and lists Grassley (R-IA) voting Yea.
Assessments
Grassley promised in the 2016 federal Senate campaign to advance bipartisan prescription drug reforms to cut prices. The evidence shows he materially advanced PBM and prescription-drug pricing reforms as an original cosponsor/sponsor-side advocate, and related PBM accountability provisions were enacted in H.R.7148/Public Law 119-75 during his continuing Senate service, with Grassley voting yes. Because the enacted reforms occurred while he remained in the same federal office and within a later elected Senate term of that continuous service, this counts as delivered with same_term timing under the provided campaign/office context.
Grassley promised to advance bipartisan prescription-drug reforms to cut prices. During the same post-2022 Senate term, he cosponsored PBM/drug-pricing reform legislation, publicly backed related PBM accountability provisions, and voted Yea on H.R.7148, which became Public Law 119-75 on February 3, 2026 and included enacted PBM prescription-drug reforms such as reporting, audit rights, rebate/discount pass-through treatment, and limits on PBM remuneration. Because relevant reforms became law in the same term, the promise is best classified as delivered.